Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 13/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 12/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.36 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
| ▸ | BRD3 | Q15059 | 3/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25122886 | 0.90 | CRBN (0.39) | CRBNDDB1IRAK4STAT3BRD3 | |
| SCHEMBL27166534 | 0.87 | CRBN (0.41) | CRBNDDB1 | |
| SCHEMBL29991108 | 0.87 | DDB1 (0.43) | CRBNDDB1IRAK4STAT3GSK3B | |
| SCHEMBL25123324 | 0.87 | DDB1 (0.43) | CRBNDDB1IRAK4STAT3GSK3B | |
| SCHEMBL25122889 | 0.82 | DDB1 (0.45) | CRBNDDB1 | |
| SCHEMBL29347154 | 0.82 | CRBN (0.41) | CRBNDDB1IRAK4STAT3HDAC6 | |
| SCHEMBL23842301 | 0.81 | CRBN (0.48) | CRBNDDB1STAT3HDAC6 | |
| SCHEMBL25123321 | 0.81 | CRBN (0.48) | CRBNDDB1STAT3HDAC6 | |
| SCHEMBL29991197 | 0.81 | CRBN (0.48) | CRBNDDB1STAT3HDAC6 | |
| SCHEMBL25123840 | 0.81 | CRBN (0.48) | CRBNDDB1STAT3HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4334307-A1 | CDK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2022236058-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |